Bispecific Or Bifunctional, Or Multispecific Or Multifunctional, Antibody Or Fragment Thereof Patents (Class 424/136.1)
-
Publication number: 20130078182Abstract: Substituted humanized, chimeric or human anti-CD20 antibodies or antigen binding fragments and bispecific antibodies or fusion proteins comprising the substituted antibodies or antigen binding fragments are disclosed. They are useful for treatment of B-cell disorders, such as B-cell malignancies and autoimmune diseases, as well as GVHD, organ transplant rejection, and hemolytic anemia and cryoglobulinemia. Substitution of an aspartate residue at Kabat position 101 of CDR3 VH (CDRH3), produces improved therapeutic properties, including decreased dissociation rates and improved CDC activity, apoptosis, B-cell depletion and therapeutic efficacy at very low dosages.Type: ApplicationFiled: September 14, 2012Publication date: March 28, 2013Applicant: IMMUNOMEDICS, INC.Inventors: David M. Goldenberg, Chien-Hsing Chang, Hans J. Hansen
-
Patent number: 8404236Abstract: The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.Type: GrantFiled: February 13, 2012Date of Patent: March 26, 2013Assignee: MedImmune, LLCInventors: Herren Wu, Peter Kiener, Partha S. Chowdhury, James F. Young
-
Publication number: 20130064823Abstract: The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof.Type: ApplicationFiled: May 5, 2011Publication date: March 14, 2013Applicant: NOVARTIS AGInventors: Feng Cong, Seth Ettenberg, David Jenkins, Ming Lei, Andreas Loew, Karen Vincent, Li Zhou
-
Publication number: 20130064822Abstract: The present invention concerns antibodies to EGFL7 and the uses of same.Type: ApplicationFiled: November 2, 2012Publication date: March 14, 2013Applicant: Genentech, Inc.Inventor: Genentech, Inc.
-
Patent number: 8394375Abstract: Phage peptide display technology was used to identify peptides that bind specifically to the amyloid form of the A?1-40 peptide. Peptides with similar structural features and bind to the amyloid form of A?1-40 but not to monomeric A?1-40, are provided. Such peptides are useful as carrier molecules to deliver therapeutic and diagnostic reagents to amyloid plaques.Type: GrantFiled: April 22, 2010Date of Patent: March 12, 2013Assignee: The Regents of the University of CaliforniaInventor: Paul Taylor Martin
-
Publication number: 20130058937Abstract: The present invention generally relates to novel bispecific antigen binding molecules. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 21, 2012Publication date: March 7, 2013Inventors: Johannes Auer, Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Wolfgang Schaefer, Claudio Sustmann, Pablo Umana
-
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
Publication number: 20130058936Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: August 21, 2012Publication date: March 7, 2013Inventors: Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umana -
Publication number: 20130058934Abstract: The present disclosure relates to antibodies targeting LRP6 and compositions and methods of use thereof.Type: ApplicationFiled: May 5, 2011Publication date: March 7, 2013Applicant: NOVARTIS AGInventors: Feng Cong, Seth Ettenberg, Felix Hartlepp, Ingo Klagge
-
Patent number: 8388965Abstract: The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.Type: GrantFiled: October 14, 2008Date of Patent: March 5, 2013Assignee: SanofiInventors: Ercole Rao, Vincent Mikol, Danxi Li, Jochen Kruip, Matthew Davison
-
Publication number: 20130039913Abstract: Heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.Type: ApplicationFiled: April 20, 2011Publication date: February 14, 2013Applicant: GENMAB A/SInventors: Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
-
Patent number: 8372399Abstract: A composition having a bispecific antibody which binds a stem cell specific antigen and a tissue, differentiated cell or condition associated antigen and an agent that enhances expression of the tissue, differentiated cell or condition associated antigen, is provided. Also provided are methods of using the bispecific antibodies and/or agents to enhance cell therapy.Type: GrantFiled: August 31, 2006Date of Patent: February 12, 2013Assignee: Cardiac Pacemakers, Inc.Inventor: Craig Stolen
-
Publication number: 20130034492Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: September 7, 2012Publication date: February 7, 2013Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Publication number: 20130028835Abstract: The present invention relates to the use of a milled homogenate and/or a suspension and/or a cell lysate, stemming from a tumor resistant to at least one anti-tumoral compound in order to immunize and generate in vitro an antibody, or one of its functional fragments, directed against a tumoral antigen specifically expressed at the surface of said resistant tumor and being possibly involved in the resistance of said resistant tumor. More particularly, the present invention is directed to such antibodies obtained by applying the method, such as the antibodies 1A6, 1A9, 2E11, 3C11 and 3G7, as well as to their use for treating cancer.Type: ApplicationFiled: July 9, 2012Publication date: January 31, 2013Inventors: Liliane Goetsch, Alexandra Jouhanneaud
-
Publication number: 20130022598Abstract: We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.Type: ApplicationFiled: May 29, 2012Publication date: January 24, 2013Applicants: The United States Government as represented by the Secretary, Department of Health and Human Service, Duke UniversityInventors: Darell Bigner, Chien-Tsun Kuan, Ira H. Pastan, Charles N. Pegram
-
Publication number: 20130022601Abstract: The present invention relates to trivalent, bispecific antibodies, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.Type: ApplicationFiled: August 7, 2012Publication date: January 24, 2013Inventors: Ulrich Brinkmann, Rebecca Croasdale, Eike Hoffmann, Christian Klein, Ekkehard Moessner, Juergen Michael Schanzer, Claudio Sustmann, Pablo Umana
-
Publication number: 20130017201Abstract: The present invention relates to a monoclonal antibody (mAb) having capabilities of binding with lethal factor (LF) as well as edema factor (EF), and neutralizing lethal toxin (LT) as well as edema toxin (ET) of B. anthracis. It also relates to process for preparation of said mAb, and to pharmaceutical preparations, anthrax diagnostic tool, in-vivo diagnostic imaging tool comprising said mAb. It also relates to genetically modified mAb, and method for prophylaxis against anthrax disease comprising administration of mAb or genetically modified mAb of present invention.Type: ApplicationFiled: March 22, 2011Publication date: January 17, 2013Inventors: Rakesh Bhatnagar, Parul Kulshreshtha
-
Publication number: 20130017200Abstract: Multispecific antibodies that specifically bind at least two different epitopes are provided. Structural variants of native antibodies (antibody analogs) are also provided. Also provided are multispecific antibodies and antibody analogs having a range of biological activities. Agonist and antagonist multispecific antibodies and agonist and antagonist antibody analogs are provided. Multispecific antibodies and antibody analogs conjugated with therapeutic and/or diagnostic agents are also provided, as are multispecific antibodies and antibody analogs conjugated with agents to increase in vivo half-life compared to multispecific antibodies and antibody analogs lacking such agents. In addition, methods of making multispecific antibodies and antibody analogs and compositions comprising multispecific antibodies and antibody analogs are provided. Therapeutic, research, and diagnostic uses of multispecific antibodies and antibody analogs are also provided.Type: ApplicationFiled: December 3, 2010Publication date: January 17, 2013Applicant: Genentech, Inc.Inventors: Justin Scheer, Richard L. Vandlen
-
Publication number: 20130011401Abstract: The present invention relates to soluble SIRP? binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRP? binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRP? binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIR % binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRP-binding antibody-like protein as shown in FIG. 1.Type: ApplicationFiled: December 21, 2010Publication date: January 10, 2013Applicant: NOVARTIS AGInventors: Thomas Huber, Frank Kolbinger, Marie Sarfati, Karl Welzenbach
-
Publication number: 20130012916Abstract: The present invention relates to formulations and methods for administering therapeutic molecules comprising immunoglobulin variable domains using needle-free delivery devices.Type: ApplicationFiled: February 10, 2011Publication date: January 10, 2013Applicants: Glide Pharmaceutical Technologies Limited, Ablynx N.V.Inventors: Christine Labeur, Hilde Adi Pierrette Revets, Nasir Hussain, Charles Potter
-
Publication number: 20130004490Abstract: The invention provides a composition comprising transthyretin and an ICAM-1 targeting agent, wherein the transthyretin and ICAM-1 targeting agent are coupled together, as well as methods of preparing such compositions. The invention further provides a diabody capable of binding specifically to ICAM-1 and transthyretin. The invention also provides a method of use of such composition in the manufacture of a medicament for treating an amyloid-? related neurodegenerative disease, comprising administering to a subject a composition comprising transthyretin coupled to an ICAM-1 targeting agent in an amount effective to treat the neurodegenerative disease, wherein the composition is administered to the subject outside of the blood-brain barrier.Type: ApplicationFiled: December 14, 2010Publication date: January 3, 2013Applicants: UNIVERSITY OF MARYLAND, COLLGE PARK, of Health and Human ServicesInventors: Juan Jose Marugan, Wei Zheng, Silvia Muro-Galindo
-
Publication number: 20130004495Abstract: The present invention relates generally to methods of using anti-NGF antibodies in the treatment of various NGF-related disorders, including pain, asthma, arthritis and psoriasis. The methods are effective in treating these disorders in a patient without having a significant adverse effect on the immune system of the patient.Type: ApplicationFiled: September 6, 2012Publication date: January 3, 2013Applicant: Genentech, Inc.Inventor: David L. Shelton
-
Publication number: 20130004498Abstract: The present invention concerns dosing of anti-EGFL7 antibodies for cancer therapy.Type: ApplicationFiled: February 1, 2012Publication date: January 3, 2013Applicant: Genentech, Inc.Inventors: Shuang Bai, Daniel S. Chen, Roel Funke, Priti Hegde, Louie Naumovski
-
Publication number: 20120328618Abstract: The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19×CD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19×CD3 bispecific antibody to a human patient having a B:T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time.Type: ApplicationFiled: October 27, 2010Publication date: December 27, 2012Inventors: Dirk Nagorsen, Peter Kufer, Gerbach Zugmaier, Patrick Baeuerle
-
Publication number: 20120328615Abstract: This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.Type: ApplicationFiled: May 25, 2012Publication date: December 27, 2012Applicant: Innate Pharma SAInventors: Francois Romagne, Pascale Andre
-
Publication number: 20120328619Abstract: The present invention relates to a molecule having binding specificities for (a) CD123; (b) CD16 and (c) CD33. The present invention further relates to the molecule of the invention, wherein the molecule comprises a first immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD123; a second immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD16; and a third immunoglobulin domain comprising a VL domain linked to a VH domain, wherein the immunoglobulin domain specifically binds to CD33. The present invention furthermore relates to a nucleic acid molecule encoding the molecule of the invention. In addition, the present invention relates to diagnostic and pharmaceutical compositions and the use of the molecule or the nucleic acid molecule of the invention in the treatment of acute myeloid leukaemia and/or myelodysplastic syndrome.Type: ApplicationFiled: December 9, 2010Publication date: December 27, 2012Inventors: Georg H. Fey, Christoph Stein, Christian Kellner, Markus Kügler
-
Publication number: 20120328616Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing B-Klotho, and or FGF21-like mediated signaling.Type: ApplicationFiled: June 1, 2012Publication date: December 27, 2012Applicant: AMGEN INC.Inventors: YANG LI, Jennitte STEVENS, Chadwick Terence KING, Ian FOLTZ, Gunasekaran KANNAN, Junming YIE, Shaw-Fen Sylvia HU
-
Patent number: 8337845Abstract: The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.Type: GrantFiled: March 2, 2011Date of Patent: December 25, 2012Assignee: Boehringer Ingelheim International GmbHInventors: John E. Park, Cornelia Dorner-Ciossek, Stefan Hoerer, Lothar Kussmaul, Martin Lenter, Katharina Zimmermann, Gerald Beste, Toon Laeremans, Pascal Merchiers, Jo Vercammen
-
Publication number: 20120321556Abstract: Disclosed herein are methods and compositions comprising interferon-? (IFN-?) and anti-CD74 or anti-HLA-DR antibodies. In preferred embodiments, the IFN-? increases the expression of CD74 and/or HLA-DR in target cells and increases the sensitivity of the cells to the cytotoxic effects of the anti-CD74 or anti-HLA-DR antibodies. The compositions and methods are of use to treat diseases involving CD74+ and/or HLA-DR+ cells, such as cancer cells, autoimmune disease cells or immune dysfunction disease cells.Type: ApplicationFiled: August 6, 2012Publication date: December 20, 2012Applicants: IMMUNOMEDICS, INC., CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGYInventors: Jack D. Burton, Rhona Stein, David M. Goldenberg
-
Publication number: 20120321553Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.Type: ApplicationFiled: May 1, 2012Publication date: December 20, 2012Applicant: IMMUNOMEDICS, INC.Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20120321626Abstract: The present disclosure relates generally to multi-specific Fab fusion proteins (MSFP) which comprise an antibody Fab fragment with both N-termini fused to a fusion moiety (fusion moiety A or B). MSFP containing the Fab fragment exhibit significantly reduced binding ability of the Fab fragment to the Fab target. Binding of the Fab to its target is restored when the MSFP is clustered on a cell surface by binding of the fusion moieties to their target. The reduced binding of the Fab to its target, especially when presented on a cell surface in its native state, absent fusion moiety binding provides advantages such as: reduced side effects and allows desirable pharmacological effects of selectivity and specificity in a controlled manner.Type: ApplicationFiled: May 16, 2012Publication date: December 20, 2012Applicant: FABION PHARMACEUTICALS, INC.Inventor: Hongxing Zhou
-
Publication number: 20120321627Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: August 9, 2012Publication date: December 20, 2012Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
-
Patent number: 8333968Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: GrantFiled: February 22, 2011Date of Patent: December 18, 2012Assignee: ZymoGenetics, Inc.Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Patent number: 8333969Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.Type: GrantFiled: August 27, 2010Date of Patent: December 18, 2012Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Tomoyuki Odani, Hideaki Tada, Kimiho Moroe
-
Publication number: 20120315216Abstract: The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides gene expression profiles associated with solid tumor stem cells, as well as novel stem cell cancer markers useful for the diagnosis, characterization, and treatment of solid tumor stem cells.Type: ApplicationFiled: July 24, 2012Publication date: December 13, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Michael F. Clarke, Rui Liu
-
Patent number: 8329169Abstract: The present invention includes compositions comprising one or more complement inhibitors and one or more CD14 pathway inhibitors for the prevention or treatment of sepsis. The complement inhibitors may be antibodies that bind to and inhibit complement proteins such as C5a and the CD14 pathway inhibitors may be antibodies that bind to and inhibit CD14 pathway components, such as CD14 and LPS. The invention also relates to methods of treating subjects suffering from sepsis comprising administering these compositions, as well as kits for supplying the compositions for treatment.Type: GrantFiled: May 14, 2004Date of Patent: December 11, 2012Assignee: Genentech, Inc.Inventors: Sek Chung Fung, Tom Eirik Mollnes
-
Patent number: 8329873Abstract: Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family.Type: GrantFiled: November 20, 2007Date of Patent: December 11, 2012Assignees: The Regents of the University of California, Fox Chase Cancer CenterInventors: Gregory P. Adams, Eva M. Horak, Louis M. Weiner, James D. Marks
-
Publication number: 20120308566Abstract: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for treating diseases, such as various forms of cancer.Type: ApplicationFiled: October 12, 2010Publication date: December 6, 2012Inventors: David Andrew Martin, Joel Tocker, Scott Baumgartner, Donna Christine Franko
-
Publication number: 20120301468Abstract: The invention provides antibodies having an antigenic binding site specifically directed against an MN protein, and methods of using such antibodies in treating and diagnosing an MN-related disorder.Type: ApplicationFiled: April 30, 2012Publication date: November 29, 2012Applicant: BAYER HEALTHCARE LLCInventors: Paul Tamburini, Gerald Ranges, Lila Adnane, Timothy McCabe, Pamela Trail, Sha Ha
-
Publication number: 20120301472Abstract: The invention concerns treatment methods using anti-CD22 monoclonal antibodies with unique physiologic properties. In particular, the invention concerns methods for the treatment of B-cell malignancies and autoimmune diseases by administering an effective amount of a blocking anti-CD22 monoclonal antibody specifically binding to the first two Ig-like domains, or to an epitope within the first two Ig-like domains of native human CD22 (hCD22).Type: ApplicationFiled: May 9, 2012Publication date: November 29, 2012Inventor: Thomas F. Tedder
-
Publication number: 20120301471Abstract: According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a pharmaceutical composition for treating and/or preventing a cancer, which comprises an antibody or a fragment thereof as an active ingredient having immunological reactivity with a partial polypeptide of CAPRIN-1, wherein CAPRIN-1 is represented by any of the even-numbered sequences of SEQ ID NOS: 2 to 30, and wherein the partial polypeptide comprises the amino acid sequence represented by SEQ ID NO: 37 or an amino acid sequence having 80% or more sequence identity with the amino acid sequence.Type: ApplicationFiled: February 4, 2011Publication date: November 29, 2012Inventors: Shinichi Kobayashi, Fumiyoshi Okano, Takanori Saito
-
Publication number: 20120294860Abstract: This invention relates to a medicament for treating and/or preventing a cancer, comprising a combination of an antibody against a cancer antigen CAPRIN-1 protein that is specifically expressed on the surface of the cancer cell, and an antitumor agent, wherein the antibody and the antitumor agent are combined together or separately, and to a use of the medicament.Type: ApplicationFiled: February 4, 2011Publication date: November 22, 2012Inventors: Takayoshi Ido, Fumiyoshi Okano, Yoshinori Narita
-
Publication number: 20120294862Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A, IL-17F, and IL-23. Antagonists include antibodies and antibody fragments that bind IL-23 and that bind IL-17A or IL-17F, such as antibodies that are cross-reactive for IL-17A and Il-17F. Antagonists that include an antibody or antibody fragment that binds IL-23 and an antibody or antibody fragment that binds IL-17A or IL-17F on one molecule are also disclosed. Antibodies and antibody fragments that bind IL-23 and IL-17F but that do not bind IL-17A are also disclosed. IL-17 and IL-23 are cytokines that are involved in inflammatory processes and human disease.Type: ApplicationFiled: June 27, 2012Publication date: November 22, 2012Inventors: Katherine E. Lewis, Scott R. Presnell, Steven D. Levin, George Robert Mabry, III, Stephen R. Jaspers, Monica J. Huber
-
Publication number: 20120294861Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.Type: ApplicationFiled: May 15, 2012Publication date: November 22, 2012Applicant: Genentech, Inc.Inventors: Junichiro Sonoda, Yan Wu
-
Publication number: 20120294863Abstract: Disclosed are CD70 binding agents, such as anti-CD70 antibodies and derivatives, that induce a cytotoxic, cytostatic or immunomodulatory without conjugation to a therapeutic agents as well as pharmaceutical compositions and kits comprising the antibody or derivative. Also disclosed are methods for the treatment and prevention of CD70-expressing cancers and immunological disorders comprising administering the CD70 binding agents to a subject.Type: ApplicationFiled: August 3, 2012Publication date: November 22, 2012Applicant: Seattle Genetics, Inc.Inventors: Che-Leung Law, Julie McEarchern, Alan F. Wahl
-
Patent number: 8309087Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin. The invention further provides a method of treating cancer in a human patient comprising administering effective amounts of an anti-ErbB2 antibody and a cardioprotectant to the patient.Type: GrantFiled: May 9, 2011Date of Patent: November 13, 2012Assignee: Genentech, Inc.Inventor: Susan D. Hellmann
-
Publication number: 20120276105Abstract: Provided are methods for diagnosing the propensity of a subject to develop skin inflammation, in particular, psoriasis. Also provided are methods of treatment with antagonists of IL-17, IL-19, and/or IL-23.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Applicant: Schering CorporationInventors: Robert A. Kastelein, Terrill K. McClanahan, Erin Murphy, Jason R. Chan
-
Publication number: 20120276106Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: ApplicationFiled: June 28, 2012Publication date: November 1, 2012Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Publication number: 20120276104Abstract: The invention relates to an antibody having at least two specificities to bind a glycoepitope and a receptor of the erbB class on the surface of a tumor cell, thereby crosslinking the glycoepitope and the receptor, which antibody has apoptotic activity effecting cytolysis independent of NK cells, a method of producing such antibody and its use as a therapeutic.Type: ApplicationFiled: March 29, 2012Publication date: November 1, 2012Applicant: f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H.Inventor: Max Woisetschlager
-
Patent number: 8298532Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.Type: GrantFiled: May 15, 2009Date of Patent: October 30, 2012Assignee: Regeneron Pharmaceuticals, Inc.Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
-
Publication number: 20120269813Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.Type: ApplicationFiled: November 5, 2010Publication date: October 25, 2012Applicants: Wayne State University, Trans Target Inc.Inventors: Lawrence Lum, Manley Huang